Back

Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Post-myocardial infarction management Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Matthew Cavender

University of North Carolina Hospitals, Chapel Hill (United States of America)

5 More presentations in this session

Presentation thumbnail
Beta-blockers improved cardiovascular outcome in AMI patients with severe heart failure: a multi-center real-world study
Doctor R. Guo (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction
Doctor S. Fang (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Antithrombotic therapy in patients with takotsubo cardiomyopathy: is heparin associated with lower mortality? - a nationwide cohort analysis
Doctor S. Hijikata (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Proton pump inhibitors in myocardial infarction: safety paradox in Type 1 vs. Type 2---a multicenter retrospective cohort study
Doctor J. Ren (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial
Professor M. Shechter (Ramat Gan, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Post-myocardial infarction management

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Hypertension and glucose
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources